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ABSTRACT 
It is currently thought that uncontrolled cellular proliferation as a result of 
cellular insults be they genetic or environmental is the major driving force behind 
the development of malignant neoplastic growth and subsequent metastatic 
dissemination. Based on the current paradigm and thinking therapeutic 
interventions for cancers specifically target rapidly dividing cells. Here, within 
this body of work is described the role that rDNA transcription plays in both the 
proliferative aspect of cancer progression as well as the role it plays in the 
metastatic dissemination of cancerous cells. Described herein is the first global 
translational analysis of the EMT program and the description of the 
coordination of two endogenous translation programs; one program that drives 
proliferation and another, independent program that drives differentiation by the 
translation of pro-mesenchymal and pro-migratory genes. 
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General Introduction 
Cancer is a worldwide problem that has been increasing in incidence as the 
worldwide population grows and ages1. There has been a significant amount of 
energy, research and time spent in trying to decipher the complexities of the 
many facets of cancer2. Progress has been made in understanding how tumors 
may be formed and what biological alterations can drive carcinogenesis1. The 
lines of evidence have pointed toward treatments that aim at stopping the 
primary tumor from growing and have mainly steered the research premises 
about cancer in the direction that the only problem is one of proliferation. 
There has slowly been a paradigm shift as more research that perhaps one 
of the most damaging aspects of cancer progression is the development of 
metastases where in some cancers like breast cancer 90% of the fatalities can 
be attributed to metastatic spread3. Building on these observations more 
research has been focused on delineating the molecular underpinnings of how 
the metastatic cascade develops, how cells survive in circulation, home into and 
colonize distant sites and finally how they begin to form secondary tumors with 
in the newly compromised tissue4–6. 
Cancer has been thought of as both a simple and a complex disease, simple 
in that a virus can cause tumorigenesis and complex in that many biological and 
cellular check points and safe guards must be overcome in order to for cancer 
development and progression to occur7–10.  In this respect cancer can be very 
complicated with multiple cellular insults giving rise to tumors and same 
principles may apply to the metastatic cascade. What has been observed 
however in both instances is that normal cellular systems can be co-opted in 
order to promote both proliferation and metastasis. 
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Though complex in nature and most likely the result of multiple programs 
acting in a synergistic manner we have chosen to focus on the Epithelial to 
Mesenchymal Transition (EMT) as potentially one of the driving forces that 
could facilitate cells with the necessary phenotypic characteristics needed in 
order for cells to leave the primary tumor11. The process of EMT involves cells 
losing their junctional adhesion molecules, rearranging their cytoskeletal 
structure, becoming more invasive and adopting the morphology of 
mesenchymal cells12,13. 
The process of EMT was first identified in the early 1960’s as a naturally 
occurring developmental process12–14. During normal developmental processes 
the EMT program is executed in order to allow for the correct migration of cells 
into the correct areas for specific tissue development. It is however thought that 
the re-activation of the EMT program during adulthood leads to disease 
states15,16. As the process of EMT has been studied and the molecular 
mechanisms identified it has mostly been studied as a transcriptionally driven 
process17–19. 
There have been several signaling pathways that have been identified and 
studied that drive or initiate the EMT program, they are Wnt, TGFb and Hypoxia 
(Notch)20–23. Within the developing chick neural tube the EMT is considered a 
Wnt driven system whereas there is evidence of TGFb and Hypoxia driven EMT 
in mammary epithelia, particularly in the context of a disease state20,24–26. 
Despite having different initiation signals there are a number of key events that 
typify an EMT program being activated of note and perhaps of key functional 
consequence is the loss of junctional proteins such as E-cadherin and b-catenin 
and the concomitant gain of mesenchymal proteins such as Vimentin and N-
cadherin17,27–29. 
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There has been prior work investigating possible translation control of 
specific proteins during the EMT process but there has yet to be any global 
translational analyses30,31. This was most likely owing to the lack of a suitable 
technique that could aid in the global analysis of which genes are actively 
translated as well as how genes are translated. In 2009 the ribosome profiling 
technique was introduced which allows for a global look at not only which genes 
are being actively translated but how they are translated32–35. 
Given the extensive nature of the transcriptional reprogramming that occurs 
as the EMT program is executed it must be complemented by a large scale 
translational change as a cell changes identity from an epithelial cell to a 
mesenchymal cell. In order to build the repertoire of mesenchymal proteins 
needed for the cellular identity switch to occur it would be necessary for there 
to be a coordinated translational program to facilitate the making of the requisite 
proteins.   In light of this hypothesis, that large scale translation changes, occur 
during EMT we sought to use a modified ribosome profiling method in order to 
get the first global snapshot of translation changes during the execution of the 
EMT program.  
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CHAPTER 1 
IMPLEMENTATION OF THE RIBOSOME PROFILING METHOD 
1.1 OVERVIEW 
In attempting to address the problem of metastatic spread, we endeavored 
to better understand the epithelial to mesenchymal transition (EMT). Though 
metastasis is a complex process, it is thought that EMT is one of the first 
processes to occur early on in tumour development that could lead to the 
dissemination of cancerous cells. 
In attempting to further delineate the molecular mechanisms of the EMT 
process we made a paradoxical observation, that rDNA transcription is 
increased despite a lack of proliferation. This is, to the best of our knowledge 
the first instance of rDNA transcription not corresponding with a cellular 
proliferation program. This finding is extensively discussed in the manuscript 
Prakash et al. of which I am a co-author. 
Given that new rDNA transcription gives rise to new rRNA and by extension 
new ribosomes we hypothesized that there must be global translation changes 
that would accompany a change in the cellular identity of one cell from an 
epithelial cell to a mesenchymal cell. In order to get a global snapshot of which 
genes are being translated as cells execute the EMT program we implemented 
the ribosome profiling protocol. 
Ribosome profiling was first described in a landmark paper by Ingolia et al 
in 2009 and offered a primary look into the power and scope of the new 
technique. By leveraging the power of next generation sequencing (NGS), the 
authors were able to come up with a strategy that minimizes bias caused by the 
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ligation protocols of most NGS systems, particularly the protocol used by the 
Illumina company for RNASeq library preparation32. 
The minimization of ligation bias was not the predominant improvement of 
this protocol however, although the changes developed in the protocol allowed 
for the overcoming of a large technical challenge, the true power lies in the 
development of a technique that can measure translation of mRNA transcripts. 
This is novel and it adds another level of biological information when combined 
with doing RNASeq studies. When combined with the transcription background 
this technique can show not only which transcripts are actively being translated 
but how they are translated. In addition to giving an idea of which transcripts are 
being translated that it can give information on upstream open reading frames 
(uORFs), alternative start sites for translation, truncated peptides, alternative 
reading frames and novel proteins35–38. This protocol was formalized and 
improved and published in 2012, it is this improved protocol that we have 
chosen to follow and modify to operate in the lab33. 
 
 
 
Figure 1. Morphology of vehicle treated (left panel) or TGFβ treated (800 pM) 
NMuMG cells (right panel) as seen at 20X magnification using phase contrast 
objective. 
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In the following protocol the NMuMG EMT cell system was extensively used 
as we were trying to determine what translational control, if any, takes place as 
cells go through EMT.  
1.2 METHOD 
1.2.1 Cell Growth and Harvesting: 
NMuMG cells grown for ribosome profiling are grown in one (1) T225 flask per 
biological repeat.  
Three (3) vehicle treated repeats are grown in three (3) T225 flasks. The same 
would be done for TGFB1 treated cells. 
Figure. 2. Schematic diagram of the work flow involved in generating Illumina 
compatible libraries from cell derived ribosome protected fragments. There are two 
main modifications to the protocol, alteration of centrifugation steps by the addition 
of a sub unit separation step and subsequent second ultra-centrifugation.  
	 7 
From one (1) T225 flask at 80 – 90% confluence (confluency here refers to what 
percentage (on average) of the 225 square cm2 area is covered by cells) would 
yield approximately 40 million cells.  
Treat the cells with cycloheximide (CHX) @ 350µM final concentration for 5 
mins @ 37 degrees (in the incubator). 
Trypsinize the cells with trypsin/EDTA (Cat#25300054) to lift the cells off of the 
surface of the flask. The NMuMG cells are adherent, thus they will stick to the 
surface). 
Gently (< 200 x g) pellet the cells at four degrees Celsius. 
Re-suspend the cells in sterile PBS (pH 7.4) in order to wash off any remaining 
trypsin or media. Pellet again gently (<200 x g). 
Re-suspend the cells in 8mL of sterile PBS (pH 7.4). I place 1 mL into a clean, 
labelled, sterile Eppendorf tube.  
Pellet the cells in a table top picofuge, aspirate as much of the PBS off as 
possible then flash freeze in liquid nitrogen. 
Store at -80°C indefinitely. 
On average, each aliquot will contain approximately 5 million cells. Using this 
methodology usually have 8 aliquots PER BIOLOGICAL REPEAT. 
As far as the protocol goes I will outline the Ingolia et al protocol 2012 and 
emphasize what is unique to our lab, what I have changed and what is the same 
as the protocol. Unless otherwise stated, the composition of the buffers has not 
been altered and should be made and used as described in the protocol. 
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1.2.2 Cell Lysis: 
(Timing: 1 hour) 
Re-suspend frozen cell pellet in 400 μL of lysis buffer. 
Lysis buffer: 
20 mM Tris (pH 7.4) 
150 mM NaCl 
5 mM MgCl 
1 mM DTT 
350 µM Cycloheximide 
1% Triton X-100 (vol/vol) 
Turbo DNase 25 U mL-1 
Thus far, I have only attempted the lysis without flash freezing as I have only 
used a mammalian cell line and have had no problems with cell lysis. 
Additionally, another graduate student (Leyi Wang) in our lab has used another 
lysis buffer mixture that gave similar yields of ribosome pellet to the one in the 
protocol (NP-40 0.5% final concentration and sodium deoxycholate 0.5% final 
concentration) of ribosomal pellets. With that in mind, I have chosen to use the 
lysis buffer from the protocol. 
1. After placing the cell lysate into a clean non-stick 1.5 mL micro-
centrifuge tube pipette cells up and down in lysis buffer to re-suspend 
and disrupt cell clumps, the more surface area the lysis buffer has to 
act the better the lysis reaction will occur. Incubate cells in the lysis 
buffer on ice for 10 mins 
	 9 
2. Triturate cells by passing them through a 25 7/8th gauge needle 10 
times.  
This serves to further break down the cell membranes and to physically 
shear genomic DNA (gDNA). This becomes important later on as the gDNA is 
degraded by DNAse treatment. As physical shearing breaks down the gDNA 
creating smaller fragments and a larger surface area foo the DNAse to work on. 
3. Clarify lysate by pelleting cell debris by centrifugation for 10 mins @ 
20 000g @ 4 °C. The Eppendorf 5424R and at 15 000 rpm gets to   
20 000g. 
1.2.3 Development of an enzymatic activity assay for Rnase I: 
As stated in the 2012 protocol33 published in Nature protocols by Ingolia et 
al. one of the most sensitive aspects of the protocol is the generation of the 
ribosome protected footprint (RPF) using the enzyme Rnase I. In order to be 
able to detect and eliminate any lot to lot variation or to be able to test the 
enzymatic activity of the nuclease it was necessary to develop an activity assay 
where the activity of enzyme could be quantified. 
It was hypothesized that the ssRNA size markers when bound to SYBR Gold 
would have a measurable signal in the 1µM concentration regime. This 
hypothesis could be directly tested using the visible blue light transilluminator 
used to take images of the RNA gels. 
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Figure 3. Left Eppendorf tube contains RNA (1µM) and SYBR Gold which 
fluoresces upon exposure to visible blue light whereas the right tube 
contains SYBR gold only and is devoid of any noticeable auto- 
fluorescence.  
Figure 4. Quantification of Rnase I activity by loss of fluorescence over time in 
different buffer conditions using a Tecan Infinite M1000 Pro microplate reader. 
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1.2.4 Nuclease Foot-printing: 
(Timing: 9 hours) 
4. Transfer 300 μL of clarified lysate to a new, clean non-stick 1.5 mL 
micro-centrifuge tube. To the 300 μL add 7.5 μL of RNase I (100 U 
μL-1). Incubate with gentle mixing @ room temperature for 15 mins. 
BE CAREFUL with tips, THEY ARE CONTAMINATED with RNase 
I, treat as if they are radioactive. Discard tips into a 50mL Falcon tube 
containing 0.01%SDS/10 mM acetic acid solution. This tube is to be 
thrown out at the end of the digestion period. In order to use either 
the nutator or the rotator I wipe the outside of the tubes down with 
0.01% SDS/ 1 mM acetic acid and I use the rotator in cell culture. 
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Figure 5. Quantification of Rnase I activity by loss of fluorescence over 
time with differing amounts of nuclease using a Tecan Infinite M1000 Pro 
microplate reader. 
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5. Add 10 μL of SUPERase.In RNase inhibitor to stop the nuclease 
digestion. Pipette up and down several times to mix. BE CAREFUL 
with tips, THEY ARE CONTAMINATED, treat as if they are 
radioactive. Discard tips into a beaker containing 0.01%SDS/10 mM 
acetic acid solution. 
ALTERATION: Instead of using the polysome buffer to make the 1M sucrose 
cushion we have opted to use a high salt buffer that consists of: 
1M NH4Cl 
20 mM Mg 2+ 
500 μM Cycloheximide 
 
The rationale behind this is that we can both inhibit the RNase I enzyme with 
the high salt. In addition, the higher cycloheximide and magnesium 
concentrations aids with keeping the ribosome locked to the message transcript 
mRNA. 
6. Transfer the digestion into a 13 X 51 mm polycarbonate 
ultracentrifuge tube. Underlay 0.9 mL of the 1M sucrose cushion 
under the sample. The sample lysate will float on top of the sucrose 
cushion, there will be a distinct and visible interface between the two 
layers. Mark the outside of the tube where you expect the ribosome 
pellet to appear. 
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7. Pellet the ribosomes by centrifugation in a TLA100.3 rotor @ 78 000 
r.p.m. @ 4 °C for 4 hours. The TLA100.3 rotor is kept in the cold room 
on the bench to the right as you enter the door. 
                  
                    
 
                      
Figure 6. Picture of the benchtop ultra-centrifuge used to pellet 
nuclease generated monosomes or pelleting of ribosome sub-
units. 
Figure 7. Picture of ribosome pellet (just above black line) 
in 51 x 13 mm polycarbonate ultracentrifuge tube. 
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ALTERATION: 
After seeing the published gels and looking at the gels I produced, it occurred 
to us that we can use a dissociation buffer to break apart the ribosome to release 
the mRNA fragments. This would give us gels with less background noise as it 
eliminates high molecular weight (HMW) RNA and it may eliminate the 
ribosomal RNA (rRNA) fragments that form a large part of the contaminating 
pool of RNA fragments that have to be depleted later on. In addition to that it 
eliminates the need for TRIzol purification of the samples and it cuts down on 
RNA processing time.  
2.2.5 Sub-unit Dissociation: 
0.5 M KCl 
1mM Puromycin 
SUPERase.In 100U / mL of buffer. 
The puromycin aids in peptide release39. The disadvantage of this alteration 
is that without the TRIzol there is no protein denaturation, this means that there 
may be active RNase I particles that may have come down with the ribosome 
pellet and they would then be released with the dissociation buffer and the be 
free to degrade the RPFs. In order to overcome this I do a subsequent wash of 
the pellet with dissociation buffer before physically disrupting the ribosome. 
Measure the diameter of the ribosome pellet with a ruler or Vernier caliper. 
8. Add 300 μL of dissociation buffer to the ribosome pellet. Incubate at 
room temperature pipette up and down until you see the ribosome 
pellet break up. This may take up to a minute of constant pipetting. 
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9. Centrifuge again in the ultracentrifuge @ 90 000 r.p.m. @ 4 °C for 2 
hours. 
                                   
10. Carefully remove the supernatant, avoid the ribosome pellet. The 
supernatant contains your RPFs. In order to purify and concentrate 
the RNA the subsequent steps describe the use of a spin column for 
both purification and concentration. 
11. Add 525 μL of 100% ethanol to the supernatant for a total volume of 
825 μL. Place 700 μL into an RNeasy™ spin column and centrifuge 
>8000 r.p.m. for 1 minute.  
12. Discard the flow-through and load the remainder of the sample on the 
column and centrifuge again @ >8000 r.p.m. for 1 minute.  
Figure 8. Picture of ribosome sub-unit pellet (right above black line) in 51 x 13 mm 
polycarbonate ultracentrifuge tube. Note the slight brown discoloration in the 
pelleted subunits. This is typical of the pelleted sub-unit pellets. 
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13. Load 700 μL of buffer RPE and centrifuge again @ >8000 r.p.m. for 
1 minute to wash the sample. Discard the flow through. Centrifuge 
again @ >8000 r.p.m. for 1 minute to dry the column.  
14. Add 50 μL of RNase free water and centrifuge again @ >8000 r.p.m. 
for 1 minute to elute RNA from the membrane. At this stage, the 
sample can be analyzed using the Nanovue for concentration and a 
small subset (~2 μL can be loaded on to a gel for an analytic look at 
it.) 
15. In order to precipitate the RNA, add 38.5 μL of nuclease free water, 
1.5 μL of GlycoBlue and 10.0 μL of 3M sodium acetate pH 5.5 and 
150 μL of isopropanol.  
The GlycoBlue is a co-precipitant and it consists of glycogen that has been 
covalently linked to a blue dye (at this moment I do not know the name of the 
dye nor its chemical structure, I do know that it is pH responsive and will turn 
pink when a solution is alkaline). This serves two purposes, it adds mass to the 
nucleic acid in order to facilitate precipitation, it is capable of precipitating nucleic 
acids at concentration on the order of 1ng / mL. In addition to making the nucleic 
acid pellet have more mass to facilitate easier pelleting it also makes the pellet 
more visible. Thus far in subsequent reactions, the GlycoBlue does not interfere 
with any downstream applications, save one, it will interrupt the ABI sequencing 
performed by Genewiz. 
16. Precipitate the RNA by chilling the mixture to -80 °C.  
In order to get nucleic acids to aggregate for pelleting we need to neutralize 
charge by adding a salt (Sodium Acetate) and an alcohol (Isopropanol), we need 
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to lower to temperature to facilitate aggregation and we need time for all of this 
to happen. I have found that 30 minutes at -80 °C will freeze the samples, in 
order to facilitate more aggregation, I remove samples after 30 minutes thaw 
them and place them back into -80 °C for another 30 minutes. 
17. Pellet the RNA by centrifugation for 30 mins @ 20 000g @ 4 °C in the 
refrigerated Eppendorf micro-centrifuge. Carefully pipette the liquid 
from the tube and let the pellet air dry for 10 minutes. 
18. Re-suspend in 5 μL of 10mM Tris (pH 8.0) 
19. Pre-run a 15% TBE-urea gel at 200 V for 15 mins in 1X TBE. 
20. Add 5 μL of 2x denaturing loading buffer to each sample. Prepare the 
size selection markers (enough for two lanes) by adding 0.2 μL of 10 
μM lower marker (18 nucleotide ssRNA marker) and 0.2 μL of 10 μM 
upper marker (42 nucleotide ssRNA marker) to 9.6 uL of 10 mM Tris 
(pH 8.0). Prepare ladder sample by adding 0.2 μL of 10bp ladder (1 
μg/ μL) to 9.8 μL 10 mM Tris (pH 8.0) 
21. Denature samples for 90 secs @ 80 °C 
22. Flush wells of gel IMMEDIATELY prior to loading, if this is done too 
early on, urea may settle back into the wells and the samples may not 
run as efficiently. Load samples using gel loading tips, ensure that 
there is no overflow between lanes. It is important to use an even 
pressure when pipetting samples into the lane as uneven pressure 
may cause spill over into other wells as the force may be too vigorous 
and the sample is displaced from the well. 
23. Run gel @ 200 V for 70 mins. 
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24. Stain with 1X SYBR Gold (2 μL into 20 mL of 1X TBE) for 3-5 minutes 
and visualize using dark illuminator (visible blue light LED illuminator). 
If you intend to take a picture of the gel with a UV transilluminator ensure 
that the gel is exposed for the minimum amount of time possible. The UV light 
is very powerful in the picture taking apparatus and it will crosslink your sample. 
This will make downstream processing less efficient and it will reduce the 
integrity of your sample. The same principle applies for the UV transilluminator 
used for cutting gel slices. Although the wavelength of light used is higher, it is 
still strong enough to cross-link your sample or degrade if exposed to the light 
for prolonged periods. Using the dark illuminator is HIGHLY recommended, the 
dark illuminator uses visible blue light that excites the fluorophores without 
damaging the oligonucleotides. 
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1.2.6 Gel Extraction: 
25. Using a fresh razor or scalpel blade cut between the two size markers, 
the RNA should be contained between the two size markers. Use a 
fresh razor blade for each gel slice in order to avoid cross 
contamination of the samples. Place each gel slice into a new, clean 
micro-centrifuge tube. 
ALTERATION:  
As recommended by the protocol the two options for gel extraction are either 
over-night extraction using an extraction buffer or a rapid gel extraction whereby 
the polyacrylamide is physically disrupted and the nucleic acid extracted from 
Untreated TGFB1 
34	NT 
26	NT 
42	NT 
18	NT 
1 2 3 4 5 6 7 8 9 10 
Figure 9. Picture of RNA gel showing the banding pattern of Rnase I digested 
ribosomes. Lane 1: Ladder. Lane 3 and 7: size selection markers, upper band (42 
Nucleotides (NT)) lower band (18 Nucleotides (NT)). Lane 2: Previous Size selection markers 
34 and 26 nucleotides (NT). Lane 4, 5, 6: untreated ribosome protected fragments. Lanes 8, 
9, 10 TGFB1 treated ribosome protected fragments. 
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it. I have not extensively tested the rapid extraction but as it relies on more 
reagents and more consumables it was not considered a viable option. Instead 
of either of these techniques, a passive dialysis method has been implemented. 
This method relies on the principle that the force generated by the concentration 
gradient should be kept at a maximal level if the extraction buffer is exchanged 
frequently. The nucleic acid is at a high concentration in the gel but a low 
concentration in the buffer, as the nucleic acid equilibrates the rate at which it 
leaves the gel eventually slows, the idea is to remove the buffer before it 
approaches saturation levels of nucleic acid thus maintaining a maximal transfer 
rate from the gel into the buffer. 
26. Add 100 μL of RNA extraction buffer to the gel slice, ensure that the 
gel slice is completely covered. Allow elution for 30 mins, then remove 
the 100 μL of buffer, place into a new non-stick micro-centrifuge tube. 
Repeat 3 more times for a total volume of 400 μL. 
It is also a good idea to cut the gel slice as thinly as possible and into 
quarters, the more surface area available for nucleic acid exchange, the better 
the results will be. 
27. Precipitate RNA by adding 1.5 μL of Glyco Blue, mixing well and then 
adding 500 μL of isopropanol. Recover RNA as described in steps 16 
and 17. 
1.2.7 De-phosphorylation reaction: 
This step is the most salt sensitive step of the protocol, the enzyme T4 
Polynucleotide Kinase is sensitive to high salt concentrations, it reduces the 
efficiency with which it operates. If for some reason this reaction is not 
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performing efficiently it may be wise to do an ethanol wash of your pellet before 
proceeding with this step. 
28. Re-suspend the size selected RNA in 10 μL of 10 mM Tris (pH 8.0) 
and transfer to a new clean non-stick micro-centrifuge tube. 
29. Prepare the de-phosphorylation reaction by adding 33 μL of nuclease 
free water to each sample. Denature samples for 90 secs @ 80 °C 
the equilibrate to 37 °C. 
30. Set up each reaction as follows: 
Component Volume (μL) Final Conc. 
RNA sample 43.0  
T4 PNK Buffer   5.0 1X 
SUPERase.In   1.0 20 U 
T4 PNK   1.0 10 U 
 
31. Incubate the samples @ 37 °C for 1 hour then denature enzyme @ 
70 °C for 10 minutes. 
Precipitate the RNA by adding 39 μL of nuclease free water, 1.0 μL of 
GlycoBlue and 10.0 μL of 3 M sodium acetate, mixing well, then add 150 μL of 
isopropanol. Recover RNA as described in steps 16 and 17. 
1.2.8 Linker Ligation: 
(Timing: 4 hours) 
32. Re-suspend the dephosphorylated RNA in 8.5 μL of 10 mM Tris (pH 
8.0) and transfer to a clean non-stick micro-centrifuge tube. 
  
Table 1. Reaction set up for 1 reaction of de-phosphorylation of RNA.  
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33. Add 1.5 μL of pre-adenylated linker (0.5 μg μL-1), denature @ 80 °C 
for 90 secs. 
Set up the following reaction per sample:  
Component Volume (μL) Final 
RNA and linker 10.0  
T4 Rnl2 buffer (10X)   2.0 1X 
PEG 8000 (50% wt/vol)   6.0 15% (wt/vol) 
SUPERase.In (20U μL-1)   1.0 20 U 
T4 Rnl2 (10 U μL-1)   1.0 10 U 
34. Incubate the reaction for 2.5 hours @ room temperature. 
This is one of the most pivotal parts of the protocol as in this step we ligate 
a known sequence of nucleotides, form henceforth it will be referred to as the 
linker, onto the unknown fragments. The linker forms the scaffold from which 
we build the corresponding parts of the library. From this addition, all 
subsequent parts of the library are built using various techniques as we seek to 
mimic the adapters used in Illumina™ sequencing. If this reaction does not work 
or is at a very low efficiency the subsequent reactions are impossible or they 
will not work to an appreciable degree. This reaction uses two key 
characteristics to accomplish a clean ligation of the unknown RNA to the known 
marker sequence, the removal of the 3’ phosphate group by enzyme T4 
polynucleotide kinase performed by the previous step and the ability of the 
enzyme T4 RNA ligase 2 truncated (T4 Rnl2) to join a ssDNA with a 5’ adenylyl 
(5’adenine with a pyrophosphate group) group to the 3’ OH end of ssRNA.  
 The ligation reaction takes place in the absence of ATP pushing the 
Table 2. Reaction set up for 1 reaction of linker ligation of RNA. 
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reaction in the direction of joining the 5’ end of the ssDNA strand to the 3’ end 
of the ssRNA. One other point to note, although the pre-adenylated marker is 
expensive do not be tempted to use it in a lower concentration, it MUST be in 
excess of your RNA fragments as this increases the odds significantly that the 
enzyme will join a linker onto an RNA fragment, the enzyme cannot join two 
linker molecules as the 3’ end of the linker is blocked by an NH2 group.  
 It is feasible that the enzyme can join two ssRNA strands if one has a 5’ 
phosphate group attached, however these reactions should be rare in 
occurrence given the excess of the linker and the concatenated ssRNA 
molecules will migrate to a different part of the gel. Last but not least, the use of 
PEG 8000 aids in the concentration of the reaction.  
 Enzymatic reactions require time and space, molecules have to be in the 
same physical space for the reaction to occur and there needs to be time for the 
reaction to occur. PEG 8000 is hydrophobic and when placed into the reaction 
mixture it pushes other molecules physically closer together it increases the 
concentration of the reaction which facilitates a more efficient reaction.  
 
 
ALTERATION: 
If the starting amount of RNA was below 1 μg then add 2 μL of T4 Rnl2 
enzyme to the reaction mixture. 
35. Add 338 μL of water, 40 μL of 3 M sodium acetate (pH 5.5) and 1.5 
μL GlycoBlue to each reaction, mix well. Then add 500 μL of 
isopropanol. Recover RNA as described in steps 16 and 17. 
36. Separate the ligation reactions by polyacrylamide gel electrophoresis 
as described in steps 19 – 23. 
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37. Excise the ligation product band and place each gel slice in a clean 
non-stick micro-centrifuge tube. Recover RNA as described in step 
26 and 27. 
1.2.9 Reverse Transcription: 
(Timing: 2 hours) 
This reaction was previously the rate limiting step in the protocol as I have 
thought it was inefficient and slow to give a sufficient quantity of product. 
However, I have discovered that this reaction, although inefficient, produces 
product even with low (< 2 pmol) starting material quantities. The product band 
that is produced is often difficult to visualize but using the amount of product 
produced in subsequent reactions produces the expected results. In order to 
Untreated TGFB1 
59	NT 
35	NT 
42	NT 
18	NT 
1 2 3 4 5 6 7 8 9 10
0 
17	NT		
Linker 
Figure 10. Picture of a gel showing successful ligation products as 
well as positive controls using the size marker. Lane 1: Ladder. Lane 
3 and 7:  Ligated size selection markers, upper band (59 Nucleotides 
(NT)) lower band (35 Nucleotides (NT)). Lane 2: Size selection markers 
18 and 42 nucleotides (NT). Lane 4, 5, 6: Untreated, ligated ribosome 
protected fragments. Lanes 8, 9, 10 TGFB1 Ligated treated ribosome 
protected fragments. 
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increase the efficiency of the reaction I have altered it by adding 1.25 more 
pmoles of primer and 200 more units of enzyme. 
ALTERATION:  
Instead of 2.0 μL of primer use 3 μL and instead of 1.0 μL of enzyme use 
2.0. 
38. Re-suspend the ligation product in 10 μL of 10 mM Tri (pH 8) and 
transfer to a clean PCR tube. 
39. Add 3.0 μL of reverse transcription primer that was reconstituted to 
1.25 μM. Denature for 2 mins @ 80 °C. Place on ice until reverse 
reaction is set up. 
 Set up the following per sample: 
Component Volume (μL) Final Concentration 
Ligation and primer 13.0  
First strand buffer (5X)   4.0    1X 
dNTPs   1.0 0.45 mM 
DTT   1.0 4.54 mM 
SUPERase.In   1.0   20 U 
SuperScriptIII(200UμL-1)   2.0 400 U 
40. Run reverse reaction at 48 °C for 30 mins. 
41. Hydrolyze the RNA by adding 2.2 μL of 1N NaOH to each reaction, 
incubate @ 98 °C for 20 mins. The GlycoBlue will turn pink. 
  
Table 3. Reaction set up for 1 reaction of reverse transcription of RNA into 
ssDNA.  
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Hydrolysis of ssRNA using high temperatures and alkaline conditions occur 
because the 2’ OH- group is susceptible to nucleophilic attack under alkaline 
conditions and high temperatures but because DNA has a 2’ H+ it is not 
susceptible to alkaline hydrolysis and thusly will not be degraded as the RNA 
will. 
42. Add 20 μL of 3 M sodium acetate (pH 5.5), 2.0 μL GlycoBlue and 156 
μL of nuclease free water to each reaction, mix well then add 300 μL 
of isopropanol. Recover ssDNA as described in steps 16 and 17. 
43. Separate the reverse-transcription products from the unextended 
primer by polyacrylamide gel electrophoresis as described in steps 
19 – 23. 
The reverse transcription primer has two hexaethylene glycol spacers 
referred to in the commercial oligonucleotide business as (SpC-18). The spacer 
consists of an 18 atom long chain of 12 carbon and 6 oxygen molecules that 
adds flexibility to the RT primer40. In addition to adding flexibility for the 
subsequent circularization step, the hexaethylene glycol spacer also acts as a 
stop point in the PCR step as it contains no nucleotides. The lack of nucleotides 
ensures that the polymerase cannot polymerize through the relatively large 
stretch of non-nucleotide atoms. It is my opinion that the hexaethylene spacers 
also causes an inordinate amount of smearing in 15% polyacrylamide-urea gels.  
When run on a gel to separate the reverse-transcription reaction there will be 
background smearing in the lanes, this occurs in the lane that contains only RT 
primer as a positive control. I believe it is a property of the primer chemistry and 
not necessarily poor gel mixing/polymerization, nucleotide degradation or any 
other part of the experiment. 
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44. Separate the reverse transcription products from the unextended 
primer by polyacrylamide gel electrophoresis as described in steps 
19 – 23. As a control, prepare one sample with 3.0 μL of RT primer 
(1.25 μM), 2.0 μL of 10 mM Tris (pH 8) and 5.0 μL of 2X denaturing 
sample buffer. 
45. Extract the DNA from the gel slices by using the methods described 
in step 26. Note it is necessary to use the DNA extraction buffer and 
NOT the RNA extraction buffer. 
46. Precipitate the DNA by adding 1.5 μL of GlycoBlue, mixing well and 
then adding 500 μL of isopropanol. Recover DNA as described by 
steps 16 and 17. 
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Untreated TGFB1 
1 2 3 4 5 6 7 8 9 10 
Figure 11. Picture of gel showing successful reverse transcription reactions. The size 
markers were used as a positive controls. Lane 1: Ladder. Lane 3 and 7:  Reverse 
Transcribed size selection markers, upper band (159 Nucleotides (NT)) lower band (135 
Nucleotides (NT)). Lane 2: RT Primer ~100 nucleotides (NT). Lane 4, 5, 6: Untreated, 
reverse transcribed ribosome protected fragments. Lanes 8, 9, 10 TGFB1 treated reverse 
transcribed ribosome protected fragments. 
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1.2.10 Circularization: 
(Timing: 1.5 hours) 
45. Resuspend the reverse transcription products in 15.0 μL of 10 mM 
Tris (pH 8) and transfer to a PCR tube. 
Prepare the circularization reaction for each sample as follows:  
Component Volume (μL) Final Conc. 
Template 15.0  
CircLigase buffer (10X)   2.0 1X 
ATP (1mM)   1.0 0.05 mM 
MnCl2 (50 mM)   1.0 2.50 mM 
CircLigase   1.0 100 U 
The CircLigase enzyme is capable of working with low amounts of starting 
template (1 pmol), I would strongly recommend using the control template 
provided with the enzyme as a positive control and to test whether or not the 
enzyme is active. With regards to the positive control, it is provided as ssDNA 
and if it circularizes the is an upward shift in how it migrates in the gel. 
Circularization is a KEY part of the procedure if it does not work the library will 
not be built correctly. As a positive control the correct fragment sizes will only 
be seen if circularization has successfully occurred. 
1.2.11 PCR amplification and Index Addition: 
(Timing: 3 hours) 
In order to generate enough material to put onto the Illumina machine one 
has to do PCR amplification and in order to run multiple samples on the same 
lane of a flow cell (referred to as multiplexing) one has to add indexing barcodes 
to the samples in order to be able to distinguish the samples from each other. 
In order to make a mixture of the correct concentration to load onto the Illumina 
Table 4. Reaction set up for 1 reaction of circularization of linear ssDNA into 
circular ssDNA. 
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flow cell the concentration of your final product has to be greater than 2 nM. The 
final concentration of the working mixture is made to 2 nM thus your sample has 
to be greater than 2 nM in order to be at the right concentration in the final 
mixture. For optimal cluster generation, it is recommended that the 
concentration loaded on the flow cell is between 8 pM – 10 pM. 
46. Set up 5 PCR strips and transfer a 16.7 μL of the PCR master mix 
into one tube in each strip. 
47. Perform the PCR with varying number of cycles, do this by starting 
the program and removing PCR tubes as the cycle number is 
reached. Be sure to let the extension be completed before removing 
the tube. Remove tubes after cycle 6, 8, 10 and 12 leaving the last 
tube in for the completion of cycle 14. 
Cycle Number Denature Anneal Extend 
1 98 °C, 30 s   
2-15 98 °C, 15 s 65 °C, 15 s 72 °C, 15 s 
 
  
Component Volume (μL) Final Conc. 
Phusion HF buffer (5X)  20 1X 
dNTPs (10 mM)  2.0 0.2 mM 
FWD primer (10 μM)  5.0 0.5 μM 
Reverse Index primer (10 μM)  5.0 0.5 μM 
Circularized DNA template  5.0  
Nuclease free Water  62  
Phusion polymerase                               1.0                           2 U 
Table 6. Temperature and times for the PCR program set up in order to run 
the PCR reactions. 
Table 5. Component volumes of each reaction component need to set up 
one PCR reaction for indexing the libraries. 
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48. Add 3.3 μL of 6X non-denaturing loading buffer to each reaction. 
Prepare a ladder sample with 0.2 μL of 10 bp ladder, 9.8 μL of 10 
mM Tris (pH 8) and 2.0 μL of 6X non-denaturing loading buffer.  
49. Separate the PCR product using an 8% non-denaturing gel, load 
amplification reaction from the same sample into adjacent well for 
direct comparison. 
50. Run the gel @ 180 V for 40 mins. Stain the gel as described in step 
24. 
51. Excise PCR product bands that are prominent but with little 
accumulation of the re-annealed partial duplex library products. Place 
these gel slices into a new, clean non-stick micro-centrifuge tube. 
52. Recover DNA from gel slices as described in steps 46 – 47 
53. Re-suspend the library in 15.0 μL of 10 mM Tris (pH 8). It may be 
stored indefinitely at 4 °C or -20 °C. 
  
 
	 32 
   
 
Untreated	 
1 2 3 4 5 6 7 8 
TGFB1 
Figure 12. Lane 1: Ladder. Lanes 2 ,3 and 4:  Indexed library for Untreated Sample 
#1, 2, 3. Lane 5 Indexed size marker positive control. Indexed library for TGFB1 
samples. Lanes 6,7, and 8 are indexed libraries. 
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Figure 13.  Schematic diagram of the finished Illumina sequencing compatible 
indexed library. All functionally important parts of the library are highlighted. 
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1.3 CONCLUSION 
Following the outlined steps above for the implementation of the ribosome 
profiling protocol yielded highly reproducible results and was the tool needed to 
get a global snap shot of translation changes that occur when cells go through 
EMT. Libraries generated are stranded, i.e. you can determine if the mRNA read 
came from the plus (+) or minus (-) strand of DNA and can be sequenced with 
Illumina single read 51 (SR51) sequencing runs. Paired end sequencing will 
NOT work as the primers are not designed for that. 
If libraries are run on a HiSeq 4000 machine, then one can expect around 
350 – 380 million reads in total for one lane.   
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CHAPTER 2 
RIBOSOME PROFILING REVEALS DISTINCT BUT COORDINATED 
TRANSLATION PROGRAMS IN EMT 
2.1 OVERVIEW 
The epithelial to mesenchymal transition occurs during normal development 
in vertebrate embryos25,41. It was first described by Dr. Elizabeth D. Hay using 
the chick embryo development system and been shown to be a naturally 
occurring process12–14. It has also been proposed that the re-activation of the 
EMT process during adulthood leads to disease states particularly16,42. These 
ideas were discussed in more detail during the general overview. 
Building off of the previous work done in implementing the ribosome profiling 
methodology it was now possible to apply it to cells that are going through or 
those that have undergone EMT using the NMuMG system43. The NMuMG EMT 
system is a TGFβ driven system where cells undergo EMT in response to the 
addition of TGFβ and perhaps more intriguingly the EMT can be reversed by 
the removal of the TGFβ stimulus23. The reversal of the EMT phenotype by the 
removal of the stimulus allows for the interrogation of how the cells revert to an 
epithelial state. 
Despite being only one of the main signaling molecules to initiate the EMT 
program the TGFβ driven NMuMG system is more amenable to the Ribosome 
Profiling technique as it offers a ready supply of material to work with, a 
controlled system in which one can efficiently trigger EMT as well as apply small 
molecule inhibitors of various key components of the TGFβ signaling pathway. 
Given the previously mentioned commonalities in the other EMT systems (Wnt 
driven or Hypoxia driven) it is possible to then test observations made in the 
NMuMG system in the other EMT systems. 
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Lastly there also exists the possibility to test whether or not any of the 
molecular players (biomarkers) that are discovered using the ribosome profiling 
technique can also be observed in human tissues. Using samples from patients 
of both cancerous and normal tissues we can get a look into how amenable the 
observations made in our model system to observations made of human 
samples. These observations would lend credence to the data and the 
possibility that upon further investigation that these biomarkers may be used for 
some clinical applications. 
  
Data generation acknowledgement: In the following figures multiple people 
contributed data for figure generation. Drs. Brittany Carson and Jennifer 
Feenstra contributed all of the immunofluorescence images and western blots 
for main text and supplementary figures fourteen (14) and fifteen (15). All 
statistical and bioinformatics analyses were performed by Dr. Matthew Parks. 
All Immunohistochemistry (IHC) data of human samples were generated by 
Varsha Prakash. Chad Kurylo performed polysome profile analyses. 
 
2.1.1 Introduction 
Ribosome catalyzed protein synthesis is central to cellular homeostasis, 
growth and proliferation and is widely recognized to be a driving aspect of 
uncontrolled cancerous cell growth and proliferation44,45,46,47. It has been 
recently shown that the non-proliferative, Epithelial-to-Mesenchymal transition 
(EMT) is considered central to metastatic disease17,48,49 requires unregulated 
ribosome biogenesis (Prakash et al.). These findings suggest that aspects of 
protein synthesis mechanism that have yet to be explored may be essential to 
reprogramming the cell for the mesenchymal state.  
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Though there has been recent progress in understanding metastatic 
spread4,5,50, the exact mechanisms underlying the dissemination of non-
proliferating cells capable of colonization secondary organ systems remain 
unclear. Cells that have undergone EMT lose junctional adhesions and gain of 
mesenchymal cytoskeletal proteins to acquire pro-invasive properties that 
enable them to leave the primary tumor site16,26,51.  During EMT the cell cycle is 
arrested with concomitant activation of pro-mesenchymal gene expression  
driven by transcription factors including, but not limited to, Snail, Smads, Twist 
and β-catenin18,19,52, which are strictly regulated at both a transcriptional and a 
translational level30,53.  
By contrast, the global translational landscape underlying gene expression 
during execution of the EMT program is less well understood. Here, we modify 
the ribosome profiling method33 to obtain genome-wide snapshots of changes 
in mRNA, tRNA and rRNA utilization pre- and post-TGFβ-mediated EMT. We 
leverage these investigations to identify and validate new biomarkers that have 
not previously been associated with EMT, including key components of the 
translation apparatus. The observed upregulation of the pro-mesenchymal 
translational program occurs during a period of reduced mTOR signaling. These 
changes were exacerbated by further reduction of mTOR signaling or by 
preventing new rRNA from being synthesized. Confirming the pervasive nature 
of the translational reprogramming during EMT, we further demonstrate that 
cells committed to the mesenchymal state are specifically sensitive to 
translation elongation inhibitors. These findings inform on potential therapeutic 
strategies for targeting and preventing the dissemination of metastatic disease. 
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2.1.2 Ribosome Profiling Reveals Novel Markers of EMT 
To investigate the translational landscape underpinning EMT, we employed 
the NMuMG mouse mammary epithelial cell line, an extensively interrogated 
TGFβ-inducible EMT model system. As expected (Prakash et al), this system 
efficiently adopted a pro-migratory, mesenchymal phenotype after 48 hours of 
TGFβ treatment, accompanied by a marked induction of rDNA transcription and 
a global reduction in protein synthesis. To examine changes in products of all 
three RNA polymerases (mRNA, tRNA and rRNA) during EMT, we performed a 
modified ribosome profiling method, in which no nucleic acid bio-type was 
subtractively removed (Fig.S14b).  
Our analysis of gene expression regulation during EMT began with 
comparisons of change in total mRNA transcription within NMuMG cells pre- 
and post-EMT and ribosome protected fragments generated from the actively 
translated mRNA pool (Fig.14a). As previously shown17,28, NMuMG cells 
treated with TGFβ exhibited a loss of the epithelial markers, including E-
cadherin (Cdh1) and coxsackie and adenovirus receptor (Cxadr), simultaneous 
with a gain in expression of the mesenchymal markers N-cadherin (Cdh2) and 
Snail (Snai1) at both the mRNA and protein level (Fig.14a; Fig.S14c). In total, 
we detected 3142 genes to be differentially expressed on a transcriptional, 
translational or transcription and translational level after 48 hours of TGFβ 
treatment (FDR < 0.05), which represents approximately 25% of all genes 
identified. Beyond the multitude of established EMT markers, we observed 
changes in a number of genes that had not been previously associated with 
EMT, including Long Non-coding RNAs (lncRNAs), small nuclear and nucleolar 
RNAs (snRNAs and snoRNAs, respectively), microRNAs (miRNAs) processed 
pseudogenes as well as mRNA transcripts (Fig.S14b).  
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To validate the association of these genes as pro-mesenchymal/EMT 
markers and the sensitivity of the ribosome profiling approach, we first probed 
the modestly increased transcriptional and translational expression of mRNA 
transcripts not previously associated with the EMT program. Cttnbp2nl was 
chosen as it is associated with stress fibers and cytoskeletal structures that 
accompany other pro-migratory and invasive cytoskeletal rearrangements54 
(Fig.S14e). Eif6 was chosen because they are directly involved in ribosome 
biogenesis55. Eif6 (also known as Tif6) binds the large ribosomal subunit to 
assist ribosome maturation and to prevent premature subunit association56,57. 
The observed transcriptional and translation changes of all markers were 
confirmed by immunofluorescence and immuno-blot analysis (Fig.14b). All 
markers were also observed to respond similarly in a second TGFβ-inducible 
EMT model, the Py2T system (Fig.14c)58,59, and after hypoxia-induced EMT in 
estrogen receptor-positive human MCF7 cells (Fig.14d) as evidenced by the 
loss of CDH1 and a gain of SNAI1 expression and nuclear localization 
(Fig.S14d). All markers also exhibited increased expression in the triple 
negative MDA-MB-231 breast cancer cell line compared to the estrogen 
receptor positive (ER+) MCF7 (Fig.14e)60. Eif6 was further shown to be highly 
expressed in the migratory neural crest cell population which have undergone 
Wnt-driven EMT25,61 that also exhibits high rRNA expression(rDNA paper) 
(Fig.14f). These new EMT markers were further validated by examining normal 
and invasive human tumor tissue samples, where in each case, invasive tumor 
samples showed increased expression (Fig.14g). These findings demonstrate 
the power of the ribosome profiling method to identify a diversity of genes 
specifically associated with the EMT program that may serve as markers of 
tumor progression and metastasis. 
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 Figure 14. Ribosome profiling demonstrates translational regulation in EMT 
coupled with transcription and identification of novel EMT markers of 
translational regulation in EMT coupled with transcription and identification 
of novel EMT markers. (a) Scatter plot of genes that are differentially expressed 
in response to TGFβ and their corresponding changes on a transcription level (x 
axis) and on a translation level (y axis) FDR <0.05 (b) Changes in protein level 
expression and localization of transcriptionally and translationally co-regulated 
genes, Cttnbp2nl (green), and Eif6 (green) in TGFβ induced EMT in NMuMG cells 
(c) Changes in protein level expression and localization of transcriptionally and 
translationally co-regulated genes Cttnbp2nl (green) and Eif6 (green) in TGFβ 
induced EMT in Py2T cells (d) Changes in protein expression of CTTNBP2NL and 
EIF6 in hypoxia (48 hours) inducible EMT in MCF7 cells (e) Comparison of 
expression levels of CTTNBP2NL (green) and EIF6 (green), in estrogen receptor 
positive cells (MCF7) and triple negative breast cancer cells (MDA-MB-231) (f) 
Chick neural crest delamination showing co-localization of eIF6 with FUrd in the 
migratory population of cells (g) Increased expression of newly identified markers, 
CTNNBP2NL and EIF6 in invasive breast cancer. Graphs depict scoring of stain 
intensity by two independent researchers. Immunofluorescence and western blots 
for panels (b,c,d) and e done by Dr. Brittany Carson. Immunofluorescence for panel 
(f) was done by Dr. Jennifer Feenstra and IHC for panel (g) was done by Varsha 
Prakash. Panel (a) was made using analysis from Dr. Matt Parks. 
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Figure S14. Ribosome Profiling Reveals Novel Markers of EMT (a) Schematic overview of 
modifications made to the existing ribosome profiling protocol (b) Graphical breakdown of all 
transcripts detected into respective categories (c) Phase contrast images demonstrating the 
morphological change that accompanies induction of EMT in NMuMG cells as well as changes 
in protein expression of established markers of EMT using both immunofluorescence and 
immunoblot (d)  Loss of the epithelial marker E-cadherin and increase in nuclear accumulation 
of the transcription factor SNAIL in response to hypoxic conditions for 48 hours in MCF7 cells 
(e) Formation of stress fibers in response to induction of EMT and visualized by Phalloidin 
staining (green). Western blots and immunofluorescence of Cdh1, Cdh2 Krt19 and Thbs1for 
panel (c) as well as all of panel (d) and (e) were done by Dr. Brittany Carson. Panel (b) was 
made using analysis from Dr. Matt Parks. 
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2.1.3 Direct Observations of Pervasive Alterations in the Translation 
Machinery  
 
 
 
 
 
 
 
 
 
  
 
Figure 15. Schematic diagram showing the key players in the eukaryotic 
translation initiation complex. Canonical translation initiation is one of the most 
studied aspect of translation as it is thought to be the rate limiting step from 
translation. Diagram taken from Bhat et al. 2015 Nature Reviews Drug 
Discovery65.  
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2.1.3.1 Canonical Translation Initiation versus Non-Canonical Initiation 
Canonical or cap-dependent translation initiation utilizes the 7methyl 
guanosine cap found on the 5’ end of many mRNAs and is considered to be the 
rate-limiting step in protein synthesis62 (Fig. 15). Translation initiation is a well-
orchestrated process involving a multiplicity of protein factors (Fig. 15) as well 
as the hydrolysis of GTP molecules in addition to several phosphorylation 
events. Given the number of components and energy expenditure involved in 
cap-dependent translation there has been a significant amount of effort spend 
on deciphering the temporal sequence of events  as well as the players involved 
in canonical translation initiation53,63–66.  
Canonical translation has been studied and implicated as being 
misregulated in the context of cancer65,67–71. We therefore examined a subset 
of translation initiation factors identified by ribosomal profiling to be 
translationally controlled post EMT including Eif3i, Eif3f and the ATP-dependent 
DEAD box RNA helicase Eif4a1 and its respective isoform Eif4a2. Given the 
recent data72,73 that Eif3 can be involved in the specific translation of proto-
oncogenic genes like c-Jun looking how components of the complex changed 
in response to EMT seemed prudent. Eif3i expression localization changed 
whereas Eif3f expression level modestly increased in line previous findings that 
increased expression is associated with a global reduction in translation69,74.  
A remarkable reduction of only one of the isoforms of the RNA helicase 
Eif4a1 was observed post EMT while a modest induction of Eif4a2 could be 
detected. This specific change in expression level of these two isoforms has 
previously been shown to be directly related to cell growth where the synthesis 
and translation of Eif4a1 is more efficient in proliferating cells compared to 
Eif4a2 which is translated in growth-arrested cells75. 
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There has however been more evidence within the literature that there may 
be more pervasive uses of non-canonical or cap-independent initiation than 
previously thought. The most studied alternative form of translation initiation is 
the use of internal ribosome entry sites (IRES) of which the cricket paralysis 
virus (CrPV) is a well-studied model76–79. This form of initiation bypasses the 
use of the 7methyl guanosine cap as well as the majority of the initiation 
complexes.  As technological advances have been made, ribosome profiling in 
particular, we have been able to observe other manifestations of non-canonical 
or cap-independent translation in particular the use of unconventional start sites, 
upstream open reading frames and the repurposing of some components of the 
canonical translation machinery34,35,63,71,80–82. 
The implications of these observations are that translation initiation is more 
complex and varied than originally thought. It adds another layer of complexity 
to the translation control repertoire that can add multiple levels of protein 
variation from the same transcriptional background.  
 
2.1.3 Translation Control is Pervasive in EMT 
We further observed that approximately 1100 genes, or 30% of those 
identified as changed during EMT, exhibited a predominant increase or 
decrease in translation efficiency (Fig. 16a). These findings suggest pervasive 
changes in the translation program during EMT. Gene ontology (GO) analysis 
revealed that the three largest mRNA subsets displaying differential translation 
were integral membrane proteins as well as components of the cytoskeleton 
and translation machineries. The latter subset included most ribosomal proteins 
as well as specific translation initiation and elongation factors (Eif3k, Eif2s2, 
Eif5a Eif4a1, Eif3f, Eif1ad, Eif4g2, Eef1a1, Eef1b2, Eef1d and Eef1g). The 
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affected initiation factors comprise distinct components required for the small 
ribosomal subunit (40S) to locate the proper start site of protein synthesis. The 
affected elongation factors ensure rapid and efficient protein synthesis. eEF1a1 
forms a ternary complex (TC) with aminoacyl-tRNA (aa-tRNA) and GTP and is 
responsible for the rapid and efficient delivery of aa-tRNA to the ribosome during 
active protein synthesis83,84. eEF1b2, eEF1d and eEF1g constitute the 
guanosine nucleotide exchange factor components for eEF1A and are thus 
responsible for maintenance of the TC pool. We validated these findings by 
performing targeted immunostaining and immuno-blotting studies on the 
modestly altered proteins Eef1b2, the main guanine nucleotide exchange factor 
(GEF) of TC and Gem, a putative GTP binding protein that has no known link to 
the translation machinery. The expression levels of both genes were confirmed 
in each in vitro EMT model system examined (Fig. 16b; Fig S16a). Strikingly, 
these studies reveal Eef1b2 to be nuclear localized after TGFβ treatment, 
suggesting the principle GEF component for TC is sequestered away from the 
translating ribosome in the mesenchymal state. The expression levels of 
EEF1B2 and GEM were also found to be similarly altered when invasive human 
tumor tissue samples were compared to normal tissue (Fig.16a,c). Remarkably, 
the nuclear localization of EEF1B2 was recapitulated in the invasive human 
tumor cell population. 
2.1.4 Translationally Downregulated mRNAs Exhibit Features 
Characteristic of mTOR Control 
To understand the underlying mechanisms giving rise to translation 
regulation during EMT, we evaluated the physical characteristics of the mRNA 
transcripts exhibiting translational control including the five prime (5’) and three 
prime (3’) untranslated region (UTR) length and 5’ and 3’ UTR folding energy. 
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In so doing, we found that genes showing reduced translation had shorter and 
less structured 5’ and 3’ UTRs (Fig.16d; S16g). These characteristics are 
typical in genes upregulated by mTOR signaling (“mTOR sensitive”)68, the 
majority of which are regulated by canonical, cap-dependent translation 
mechanisms85. This finding is consistent with the global reduction in protein 
synthesis evidenced in cells and in polysome profiles (Fig.S16e; S16f). 
Consistent with these findings, we observed that mTOR signaling was reduced 
post EMT evidenced by reduced expression of total mTOR kinase (shared 
between mTORC1 and mTORC2 complexes), mTORC2 mediated Akt 
phosphorylation, pS473, and Akt mediated phosphorylation specific mTORC1 
mark pS2448, were all reduced post EMT. Further evidence of reduced mTOR 
signaling was displayed by reduced Rps6 phosphorylation and increased eIF2α 
phosphorylation in both NMuMG and MCF7 cells (Fig.S16c,d). That reduced 
mTOR is a conserved feature of the EMT program was further supported by 
expression studies of increased eIF2α phosphorylation in the chick developing 
embryo. The downregulation of mTOR likely contributes to the non-proliferative 
status of the mesenchymal state68,86,87. 
 The inverse relationship between TGFβ and mTOR signaling was 
confirmed by serum-starving NMuMG cells in the absence and presence of 
TGFβ treatment. These investigations demonstrated that serum starvation 
further reduced mTOR signaling and intensified the EMT program as evidenced 
by morphological changes, induced Vimentin and N-cadherin expression and 
increased invasive capacity (Fig.S16h). These observations are consistent with 
observations that mTOR inhibition can induced a paused pluripotent stem cell-
like state22,48,88,89.  
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2.1.5 Translationally Upregulated mRNAs Exhibit Features Characteristic 
of Oncogenes 
By contrast, the genes translationally induced by TGFβ were typified by 
longer and more structured 5’ and 3’ UTRs (Fig. S16g). Such features have 
been shown to be enriched in oncogenes implicated in tumor progression that 
exhibit non-canonical, cap-independent translation mechanisms63. In the 
present dataset, three of the 23 genes previously validated as bona fide 
tumorigenesis promoting, IRES-containing cellular mRNAs (Egr2, VEGFA, 
Jun,)63 were observed to be translationally upregulated.  
In addition to Gem and Vimentin (Fig. 16a), the translationally upregulated, 
pro-mesenchymal transcripts induced by TGFβ included integral membrane 
proteins (Adgrg1, Jak2, Klrg2, Slc4A1, Slc8a1, Slc25A25, Ttyh1), chromatin 
modifiers (Bahcc1, Clmn, Fam60a and SkiL), transcription factors (Cebpb, Csl, 
Foxp1, Foxo6, Fosb, Fosl2, Irf1, Junb, Klf10, Maf, Runx1t, Stat2/3), cytoskeletal 
proteins (Krt78, Synpo2l. Tubd1, Wipf2), RNA binding proteins and helicases 
(Rmrp, Stau1, Mov10, and Ddx3x/24/52) as well as specific translation factors, 
ribosomal proteins and regulatory factors of translation (eIF2AK4, eIF3F, 
eIF1G1, eIF4A2, eEF1A1, , Rps12l1and Klhl25). Interestingly, we were also 
able to identify over 40 genes whose functions have yet to be fully elucidated. 
Of the genes whose functions have yet to be elucidated over 30 genes are from 
transcripts that were predicted using in silico methods, several of which are for 
snoRNAs, pseudogenes and one gene that is a predicted protein coding gene 
(A830018L16Rik). In addition, a number of small, stable RNAs were also 
identified as being translationally upregulated in TGFβ-induced EMT, which 
means that they either bind to, or pellet as high-molecular weight species 
alongside ribosomes. These including, snRNAs (Rnu1a1), snoRNAs 
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(snora3/65/73a/73b/74b/78, snord12/73a/80/83b/100), the RNA component of 
RNase P (Rpph1), which is required for tRNA processing, microRNAs 
(Mir21a/22/24-1/27a/27b/29a/30b/99b/125-b2) and long non-coding RNAs (7S 
RNA, Malat1).  
 Recent literature70,90–92 now indicate that mRNA translation elongation 
also plays a key role in this fundamental process and the control is far more 
complex and dynamic than previously anticipated as it is determined by the 
complex interactions of tRNA, mRNA and elongation factors coupled with 
dynamics of the ribosome itself.  To initiate a successful round of translation 
elongation Eukaryotic Elongation factors 1A (eEf1a) and ternary complex (TC) 
containing the amino acylated tRNA and eukaryotic guanine nucleotide 
exchange factors (GEFs), Eef1b2 and Eef1d, together with the scaffolding 
protein Eef1g needs to engage on the mRNA transcript and Eef2 subsequently 
aids in the translocation of tRNAs along the mRNA transcript93.  
As Eef1b2, the main GEF responsible for delivering tRNA was altered on a 
translation and a localization level during EMT (Fig. 16b) we investigated the 
localization and expression of the remaining components of the TC and only 
Eef1b2 was altered (Fig. 16f).  
Subsequently, we determined the level of Eef2 and the inactive, 
phosphorylated form of Eef2 (pEef2) which displays reduced ribosome binding 
and has therefore been shown to reduce the elongation process 94,95. We 
observed increased expression and confirmed nuclear localization of pEef2 in 
cells that have undergone TGFβ mediated EMT by co-localization with Smad4 
(Fig. 16f).  
It is known that mTOR signaling regulates the activity of the Eef2 kinase and 
Eef2 is kept in a predominantly non-phosphorylated state to support efficient 
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elongation90. Thus the increase in inactive pEef2 is in line with the reduced 
mTOR signaling during EMT presumable through reduced efficiency of 
translation elongation. Collectively, the expression and localization changes of 
initiation and elongation factors further substantiate that global and pervasive 
changes in the translation machinery occur post EMT. 
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Figure 16. Polymerase profiling demonstrates translational regulation in EMT 
independent of transcription. (a) Pie chart illustrating that approximately 40% of 
all differential genes are translationally controlled (b) Change in both the 
expression and localization of the protein Eef1b2 in TGFβ driven EMT in NMuMG 
cells as well as hypoxia (48 hours) driven EMT in MCF7 cells. (c) Increased 
expression and nuclear localization of EEF1B2 and GEM in invasive cancer as 
compared to normal tissue (d) Violin plots illustrating that, on average, the mRNA 
transcripts of genes that were up-regulated in cells undergoing EMT had longer 5' 
and 3' UTRs p < 0.05) (e) Immunofluorescence using phospho-specific antibodies 
demonstrate the pS2448 on mTOR and pS473 on Akt are lost (f) 
Immunofluorescence of NMuMG cells showing alteration in both expression and 
localization of initiation factors as well as changes in localization and expression of 
elongation factors including the phosphorylated form of Eef2. Panel (a) was made 
using analysis from Dr. Matt Parks Immunofluorescence and western blots for 
panel (b) were done by Dr. Brittany Carson. IHC for panel (c) was done by Varsha 
Prakash. Panel (d) was produced by Dr. Matthew Parks and modified by me.  
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  Figure legend and data attributes are on the following 
page. 
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Figure S16. Loss of mTOR and gain of pro-mesenchymal mediated translation during 
EMT. (a) Increase in nuclear localization of Eef1b2 in the TGFβ induced system Py2T as well 
as the TNBC cell line MDA-MB-231 vs MCF7 human breast cancer cell lines (b)Nuclear 
localization of Gem in the Py2T system as well as the human cell lines MCF7 and MDAMB231 
(c) Reduction in the expression and phosphorylation of Rps6 at Serine 240/244 in response 
to TGFβ (d) increase in the phosphorylation of the alpha subunit of Eif2 indication a reduction 
in mTOR driven and cap dependent translation in NMuMG cells. In hypoxic condition with 
MCF7 cells though the phosphorylation status of the alpha subunit was unchanged there was 
a significant loss of the GEF EIF2B which has the same overall effect. (e) Polysome profiles 
depicting the active translating pool from either vehicle treated or TGFβ treated cells 
demonstrating that there is an overall reduction in global translation in response to EMT. (f) 
Global reduction in protein synthesis in response to TGFβ as shown by Click iT OPP 
fluorescent assay. (g) Violin plots comparing the 5’ and 3’ folding energies of repressed and 
induced mRNA transcripts in response to TGFβ of genes changed only on a translation level. 
(h) Comparison and quantification of the increase in expression of either Vimentin or N-
Cadherin in either a serum starved or serum present state in addition to the proliferative status 
of the cells as demonstrated by the presence of EdU. Graphs of the relative fluorescence 
intensity are below representative images of each condition. Quantification of the increase in 
the invasive capacity of cells that have gone through EMT in a serum starved state as 
compared to those in a serum added state. Western Blots and immunofluorescence for panels 
(a,b,d,h)  were done by Dr. Brittany Carson. Polysome Profiles for panel (e) were done by 
Chad Kurylo. Panel (g) was made by Dr. Matthew Parks and modified by me. Invasion assay 
was performed by Varsha Prakash. 
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2.1.7 Inhibition of Ribosome Biogenesis and TGFβ Removal Reverses 
Translational Control 
The EMT program is phenotypically inhibited, and can be at least partially 
reversed, by administration of CX-5461 or by removal of TGFβ (Prakash et al). 
To demonstrate gene expression control of pro-mesenchymal translational 
program we interfered with de novo rRNA biogenesis using the RNA 
Polymerase I assembly inhibitor, CX-546196,97. NMuMG cells, which had 
initiated but not completed the EMT program (27 hours of TGFβ treatment), 
were treated with 100nM CX-5461, a time point and concentration that has no 
observable impact on DNA replication or apoptotic pathways (REF rDNA). By 
comparing ribosome profiling and RNASeq data, we detected that CX-5461 
treatment reversed the impact of TGFβ for almost 30% of the 1000 genes 
identified as being translationally controlled (Fig.17a). Remarkably, CX-5461 
treatment had no significant changes on transcription, suggesting that the 
observed impacts were solely dependent on the inhibition of ribosome 
biogenesis.  
As expected, the physical characteristics of the mRNA transcripts 
translationally induced by CX-5461 treatment corresponded to relatively short, 
unstructured 5’- and 3’-UTRs typified by mTOR sensitive genes; mRNA 
transcripts that were translationally repressed had the pro-mesenchymal/pro-
invasive signature of relatively long, structured 5’- and 3’-UTRs (Fig. 17b). To 
verify that mTOR signaling had reversed in line with the mRNA transcript 
profiles, we investigated total mTOR, AktpS473 and mTORC1pS2448. As 
predicted by the mRNA transcripts CX5461 treatment resulted in a small 
induction mTOR, pAkt and mTORC1 mark pS2448 supporting the notion that 
mTOR signaling is induced post treatment (Fig. 17c). Interestingly, the 
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observed reduction in the RNA helicase, Eif4a1 post EMT was reversed post 
CX5461 treatment (Fig. 17c). To verify that the pro-mesenchymal program was 
reduced we investigated Gem and Vimentin expression and as predicted 
detected reduced expression of both proteins (Fig. 17d).  
TGF is secreted as an inactive latent complex together with latency-
associated proteins (LAPs) where it subsequently binds latent TGFβ-binding 
protein (LTBP). Both proteins must be liberated from TGFβ for it to be active as 
a cytokine. Three of the four known members of LTBP protein family (LTBP 1,3 
and 4) were identified in our gene set and two of them, LTBP 1 and 3, were 
observed to reverse translationally efficiency upon CX5461 treatment (Fig. 
17a). Thrombospondin-1 (Thsb1), an extracellular matrix glycoprotein 
implicated in TGFβ activation, was also reversed upon CX5461 treatment (Fig. 
S17d). These findings suggest that CX-5461-mediated inhibition of ribosomal 
biogenesis directly or indirectly interferes with the translationally efficiencies of 
autocrine loop proteins responsible for TGFβ secretion and activation. Parallel 
changes in global translational efficiency were observed for 330 of 1100 
transcripts found in the CX-5461-impacted gene set when TGFβ was removed 
from the NMuMG growth media after 48 hours of treatment. 
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Figure 17. Gene expression is altered by use of a Pol I specific inhibitor. (a) Scatter 
plot showing the reversal of a subset of genes that were differential only on a translation 
level in response to the Pol I inhibitor CX5461 (100 nM) (b) Violin plots illustrating that 
the genes that were repressed in response to CX5461 had, on average, longer 5' and 
3' UTRs p<0.05. Whereas genes induced by CX5461 had, on average, shorter 5’ and 
3’ UTRs p<0.05 (c) Immunofluorescence using phospho-specific antibodies 
demonstrating the reduction of phosphorylation at serine 473 and 2448 of Akt and 
mTOR respectively as well as the loss of expression of Eif4a1. The phospho-marks as 
well as Eif4a1 expression are regained upon treatment with CX5461 (d) 
Immunofluorescence demonstration the gain in expression of Vim and Gem and 
subsequent reduction in expression in response to CX561 with the corresponding 
quantification of the fluorescence signal. Panel (a) was made from analysis by Dr. Matt 
Parks (b) was produced by Dr. Matt Parks and modified by me. Immunofluorescence 
and quantification for Panel (d) was done by Dr. Brittany Carson. 
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Figure S17. Pol I assembly inhibition can reverse gene expression (a) 
Fluorescent images of EU staining in NMuMG cells both in response to TGFβ and 
plus and minus CX5461 100nM for 24 hours. (b) Folding energy for 5’ and 3’ UTRs 
of CX5461 induced or repressed transcripts p < 0.05. (c) Change in localization of 
P70S6K to the nucleus in response to TGFβ and change in localization from the 
nucleus to the cytoplasm with CX5461 treatment for 24 hours. (d) Scatter plot of 
genes that were either induced or repressed at a translation level in response to 
the removal of TGFβ. Panel (b) was made by Dr. Matt Parks and modified by me. 
Panel (d) was made by me using analysis from Dr. Matt Parks. 
	 57 
2.1.8 tRNA Genes are Differentially Utilized During EMT and Inhibition of 
Ribosome Biogenesis or TGFβ Removal Reverses the tRNA Gene 
Signature 
The tRNA adapter molecule facilitates mRNA decoding during protein 
synthesis and serves as an integral component of the elongating ribosome by 
influencing factor interactions and functional ribosome dynamics98–100. Specific 
tRNA species have recently been implicated in regulating cell proliferation and 
metastasis101–103. Given the global changes in mRNA transcripts and the 
pervasive expression and localization changes of initiation and elongation 
factors in, we next asked whether additional components of the translation 
machinery, tRNA was altered to accommodate the EMT switch.  Given that the 
tRNAs retrieved were derived from pelleted ribosomes we refer to this pool of 
tRNAs as “utilized tRNAs” as they represent a snap-shot of the tRNAs being 
used by the ribosome in active translation. A bioinformatics strategy was 
developed where we retrieved amino acid, anti-codon and gene level 
expression data. We observed a modest decrease in the global utilization of 
Ala, Val, Glu and Lys tRNA isoacceptors and modest increases in Cys, Gln, Ser, 
Trp, Met, Leu and His tRNA isoacceptors (Fig. 18a).  The remaining tRNA 
isoacceptor families exhibited both increased and decreased utilizations for 
specific isoacceptor sub-types.  
Importantly, we could identify and map reads to 197 tRNA genes out of the 
260 sequentially distinguishable tRNA genes within the genome, of which, 68 
genes (38%) were differentially utilized post TGFβ treatment, resulting in the 
first identification of a specific subset of tRNA genes that are utilized during EMT 
(Fig. 18a). Interestingly, in our gene set the tRNA gene GluUUC which has 
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previously been linked to metastasis was identified to be utilized to a larger 
extent by the ribosomes post TGFβ treatment102 (Fig. 18a). To identify if this 
tRNA signature was due to TGFβ signaling and under translation control we 
analyzed tRNA transcripts utilization with the removal of TGFβ treatment and in 
the presence of CX5461 (Fig. 18b).  Of the 68 tRNA genes shown to be 
differential in response to TGFβ, 27 (41%) were reversible when TGFβ was 
removed (washout) and 24 (36%) were reversible when CX5461 was used. 
There was a large overlap where 88% of the tRNA genes were found to be 
reversible in both conditions suggesting that tRNA utilization by the ribosomes 
is dependent on the translational changes evoked by the TGFβ signaling. 
Although we cannot conclusively argue that such changes exclusively reflect 
changes in the elongating ribosome’s composition given that high-molecular 
weight tRNA synthetase complexes may pellet alongside ribosomes during the 
profiling procedure, these data minimally suggest that the available TC pool is 
globally altered during TGFβ-induced EMT. 
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2.1.9 rRNA is Altered During EMT and Inhibition of Ribosome Biogenesis 
and TGFβ removal Reverses the rRNA Changes 
The final component and major component of the ribosome is rRNA. Since 
we did not apply subtractive hybridization of rRNA nor bioinformatically removed 
rRNA, we retrieved, in an unbiased manner, cleaved rRNA from exposed areas 
of the ribosome. As the nuclease Rnase I is enzymatically probing solvent 
Figure 18. (a) Histogram showing the changes in expression to specific tRNA 
genes (b) Scatter plot of tRNA genes that are reversed either in response to 
CX5461 100nM for 24 hours or to TGFB removal for 48 hours (WO). The top 
histogram was produced by Dr. Matthew Parks. The bottom scatter plots were 
made using analysis by Dr. Matt Parks 
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accessible areas of the ribosome and given the preference of Rnase I for single 
stranded RNA any secondary structure changes, in the rRNA will give rise to 
differential digestion products in a context dependent manner33,104,105. A 
differential digest could also arise from changes to the protein composition of 
the ribosomes or differential biding of auxiliary translation factors. Given the 
observed altered elongation efficiency detected in EMT we specifically asked 
whether changes in the ribosome in close proximity to the Eef2 binding site 
could be detected. As the sequence of the rDNA operons in the NMuMG cells 
are not currently known we instead mapped the retrieved rRNA fragments to 
the structure of the human 80S ribosome (PDB 3J3A, 3J3B, 3J3D and 3J3F) as 
the structure of the mouse ribosome has not been determined106. A subset of 
reads mapped to areas in close proximity to the Eef2 binding site and post TGFβ 
treatment, the retrieved reads were significantly altered 5 log2 (32 fold) 
suggesting that enzymatic access of that area was altered (Fig. 19a). 
Collectively this argues that alterations in the binding affinities or frequency of 
auxiliary factors may manifest itself as areas of differential digests. 
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2.1.10 Translation Elongation is Altered During EMT such that translation 
elongation inhibitors selectively target cells in the mesenchymal state 
 Translation elongation requires the coordination of two key complexes; 
Given the key role Eef2 plays in the translocation of tRNAs during the elongation 
phase, we next assessed whether the changed Eef2 would alter the time 
ribosomes stay in a specific conformational state. It has recently been shown 
that the distribution of mRNA fragment lengths can be linked to the confirmation 
state of the ribosome where un-rotated state of the ribosome mimics a post-
termination state of the translation cycle, thus implicating a successful round of 
translation has occured107.  
 Based on the pervasive changes to the translation machinery including 
tRNA, rRNA and specifically elongation factor and TC accessibility to 
accommodate the EMT switch we tested whether cells transitioning from an 
epithelial state to a mesenchymal state will respond differently to translation 
Figure 19. (a) PyMol figure of differentially digested areas of the ribosome. With inset 
of a zoomed in and rotated view of Eef2 in direct contact with the areas of the ribosome 
that show large digest changes. The PyMol session utilized analysis by Dr. Matt Parks  
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elongation inhibitors. Accordingly, we treated NMuMG cells in the presence or 
absence of TGFβ with increasing concentrations of the translation elongation 
inhibitor Didemnin B. Cells undergoing EMT were much more sensitive to 
Didemnin B, as we observed little to no cell death in control cells, while we 
observed pronounced killing of cells that were exposed to TGFβ in line with EMT 
cells displaying marked differences in translation elongation efficiency (Fig. 
20a,b). 
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Figure 20. (a) Phase contrast images of vehicle and TGFB1 cells either with 
addition of 100 nM Didemnin B or DMSO. (b) Graph of the quantification of cell 
number versus Didemnin B concentration showing differing effects on TGFB 
treated cells. 
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2.2 DISCUSSION 
The regulation of the cell identity switch of EMT has primarily been attributed 
to transcriptional regulation with few studies indicating a contributing role of 
translation regulation18,41,52. Building upon our previous findings demonstrating 
an increase in rDNA transcription during EMT in the absence of proliferation, 
we employed a modified ribosome profiling method and identified that pervasive 
genome-wide translation regulation occurs during EMT. Importantly, we 
identified that the translational changes that occurs during EMT involves the 
translation machinery and components thereof. Three novel EMT markers Eif6, 
Eef1b2 and Cttnbp2nl were identified and expression changes of these proteins 
were shown to be generalizable irrespective of EMT stimuli. Importantly, all 
invasive tumor samples showed increased tissue expression of the newly 
identified EMT markers compared to normal tissues suggesting that these new 
markers may have clinical relevance as prognostic indicators of invasive 
disease in combination or separately108,109. Further clinical studies including 
more human tissue samples will be required to address this in more detail. 
By the genome-wide analysis of translation control during EMT, we 
unexpectedly identified that the mRNA transcripts which were reduced, had 
shorter and less structured 5’ and 3’ UTRs, all characteristics of mTOR sensitive 
genes (Fig 16d; S16g)68,85. Prior literature has elegantly shown that reduced 
proliferation is necessary for cells to undergo EMT but mainly on a gene specific 
transcriptional level. Our data provides a compelling explanation as to how this 
switch is mediated on a global and translation level by the reduction of mTOR110. 
Building on that observation in the context of an even further reduced mTOR 
signaling milieu we were able to induce an augmented EMT including increased 
invasiveness. Reduced mTOR signaling has mostly been associated with an 
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amino acid starvation state and despite that global translation is reduced (Fig. 
S16c, S16f) we observe that it can be further reduced by serum starvation45,87. 
This argues that during a nutrient limited state, such as within in a rapidly 
expanding tumor mass, cells are not prevented from undergoing EMT, rather it 
suggests that during some starvation states i.e. hypoxia, may instead promote 
EMT. Indeed, previous studies have already demonstrated that hypoxia reduces 
mTOR signaling and hypoxia has been shown to induce EMT21. Our data 
argues that the link between the two may at least partly, lie in restricting the 
canonical translation mTOR-dependent proliferative program to promote the 
non-canonical, pro-mesenchymal migratory translational program. Moreover, it 
has been reported that cells that transition from an epithelial state to a 
mesenchymal state can adopt a stem cell like phenotype as well as the need 
for an inhibition of mTOR in order to induce a paused pluripotent state22,48,88,89. 
This notion is further supported in that we also observe similar EMT markers 
being changed in our hypoxia induced EMT model (Fig. S14d) and that markers 
of cap-dependent translation are reduced (Fig. S16d).  The genes 
translationally induced by TGFβ were instead typified by longer and more 
structured 5’ and 3’ UTRs (Fig. 16d; S16g) which have been shown to be 
feature of oncogenes translated by non-canonical, cap-independent translation 
mechanisms63. That these translational programs are remarkable coordinated 
on a global level to reduce proliferation and promote EMT was shown by 
inhibition of ribosome biogenesis by CX5461 and TGFβ removal resulted in 
reversed of these translational programs. Subsequently mTOR program was 
regained and the pro-mesenchymal program reduced. 
It has previously been shown that mTOR signaling activates rDNA 
transcription in order to promote cell division45,111. We therefore conclude that 
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the observed increase in rDNA transcription must be driven by a distinct and 
mTOR independent signaling cascade, uncoupling mTOR-dependent rDNA 
transcription during cell growth from mTOR independent rDNA transcription 
during EMT. These data also argue that rDNA transcription during EMT 
regulates the mTOR translation control as perturbation by CX5461 and by 
extension the making of new ribosomes induces the mTOR sensitive genes and 
reduces the mTOR insensitive genes without any detectable transcriptional 
changes.    
Recently, it has been recognized that tRNAs play an important role in 
translation during disease states and aberrations in tRNA expression may be 
sufficient to induce disease states103,112,113. There has been evidence that 
proliferating cells utilize a different tRNA gene set than differentiating cells thus 
suggesting that there are distinct tRNA programs for different cellular programs. 
Our experimental strategy and retrieved data substantiates this observation, as 
we observe tRNA utilization differences during EMT101,113.  In line with reduced 
mTOR signaling we also observe a decrease in the utilization of tRNA genes 
coding for the amino-acids that induce mTOR signaling such as leucine, 
arginine and serine. In line with the mRNA transcripts changing, perhaps the 
most striking observation was the change in the utilized tRNA signature with 
CX5461. These results directly link the tRNA gene set used for the translation 
of specific mRNA transcripts and when de novo ribosome biogenesis is halted 
the utilized tRNA gene signature changes. Interaction between the ribosome, 
tRNA and initiation factors has previously been indicated to be involved in the 
efficiency by which translation can occur. It could also indicate a feedback 
mechanism where disruption of Pol I transcription leads to changes in Pol III 
transcription thus altering the expression of a specific tRNA gene set. It has 
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previously been shown that there are communication between the Pol I, Pol II 
and Pol III as Pol III transcribes a physical component of the ribosome (5S 
rRNA) in addition to tRNAs114. One implication of this observation is that the Pol 
I specific inhibition alters the rRNA pool and correspondingly the tRNAs that are 
used in executing of the EMT program. These observations are intriguing 
particularly given the recent findings that specific tRNA gene expression can 
lead to specific genes being translated more efficiently and directly affecting 
metastatic outcome102,115. 
 It has been widely known within the translation field that the process of 
elongation is crucial for mRNA translation and that this process is highly 
dynamic, transient and is directly regulated by the interactions of tRNA, mRNA 
and elongation factors coupled with dynamics of the ribosome itself. These 
observations have been elegantly elucidated using cryo-EM and smFRET of 
ribosomes in various translation elongation stabilized states116. Depending on 
the configuration of the ribosome and which components are actively engaged 
with the translating ribosome, at a given time, will directly affect the translation 
elongation dynamics117. So far these mechanisms have only been studied in the 
context of in-vitro re-constituted ribosomes where labeled complexes of the 
ribosomes have been followed in real-time. Given that the mRNA, tRNA and 
dramatic changes to the components of the elongation machinery including 
Eef1b2, we interpret that the elongation dynamics of ribosomes differ in EMT 
cells. Eef1b2 is one component of a hetero-trimer protein where it acts as the 
main guanosine-nucleotide exchange factor (GEF)93. The bacterial homolog of 
the eukaryotic GEF is Ts and has been shown to aid in the formation and 
dissociation of TC which comprises of amino-acylated tRNA and an elongation 
factor Tu, responsible for delivering the appropriate tRNA to actively translating 
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ribosomes118. In bacteria it has been shown that formation of TC is lower in the 
absence of Ts thus translation can occur albeit with a lower elongation 
efficiency119. Given that the mammalian homolog of Ts, Eef1b2, performs a 
similar function, changes in the cytoplasmic concentration would affect the 
speed and/or efficiency of ternary complex formation and therefore slow down 
the rate of ternary complex formation and by extension the rate of translation. 
To the best of our knowledge, this study is the first to demonstrate that 
components that aid in the formation of TC is modulated in response to 
extracellular signaling in a mammalian cellular system. Most strikingly is the 
redistribution of the protein from a predominantly cytoplasmic localization to a 
previously unreported nuclear localization whereas there were no observable 
changes in the localization of Eef1g or Eef1d (Fig. 16f) and that this nuclear 
expression also is found in the human invasive tissue samples. Although 
nuclear localization has not previously been reported for Eef1b2, Eef1a has 
previously been reported to play an important role in regulating the nuclear 
export of SNAG domain contain proteins such as Snail in EMT120.  This also 
opens up the possibility that Eef1b2 might display an as yet unknown function 
in the nucleus. Further evidence of translation elongation alterations during EMT 
was evident by the increased expression of the inactive phosphorylated Eef2 
and its corresponding localization to the nucleus. In a similar manner to the 
nuclear localization of Eef1b2, the TGFβ dependent localization of pEef2 raises 
the question whether it plays an unanticipated role in the nucleus. A decrease 
in Eef2 activity has been shown to impact the translocation step of translation 
and our data corroborated this by demonstrating that the conformation of the 
ribosomes in cells post EMT were predominantly in a rotated state indicating 
that measurable differences in translation elongation has occurred. More 
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importantly these alterations in translation elongation rendered cells which were 
going through or had gone through EMT more sensitive to translation elongation 
inhibitors and were selectively killed by elongation inhibitors such as Didemnin 
B leaving the control, untreated cells modestly unaffected.   
To gain further insight into the pervasive elongation changes during EMT we 
also investigated rRNA, the major constituent of the ribosome in areas in close 
proximity to Eef2. Our modified protocol allowed us to detect differences in the 
digested rRNA providing evidence that the ribosomes in the cells post EMT 
might be composed of different proteins or display differential biding of auxiliary 
translation factors. These digest differences were reversed in a TGFβ and 
CX5461 dependent manner suggesting that these changes mirror tRNA and 
mRNA changes. Within the limit of the experimental design we could not 
specifically elucidate how these digest differences arose and specifically what 
physical constituent of the ribosome or its interacting partners gave rise to the 
digest patterns. The observations are provocative and further biochemical 
analysis will be required in order to fully understand the mechanism behind the 
observed changes in rRNA.  
We show that all products of the three known RNA polymerases are altered 
in the EMT process and more importantly our data strongly argues the existence 
of two specific translation program that needs to be regulated to execute the 
EMT program, a reduction in the mTOR dependent and induction of a pro-
mesenchymal translation program. By perturbing the making of de novo rRNA 
by CX5461, we believe that the context specific ribosomes generated in EMT 
will utilize a specific set of tRNAs, elongation factors to translate the necessary 
pro-mesenchymal mRNAs enabling the cell to switch its identity from an 
epithelial cell to a mesenchymal state. These findings also highlight one 
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possible explanation as to why anti-proliferative drugs are ineffective at stopping 
metastatic spread and outlines an alternative therapeutic strategy whereby the 
use of translation inhibitors in combination with anti-proliferative drugs may 
more effectively combat metastatic spread. Further understanding of translation 
regulation and the mechanisms that underlie those changes are required and 
warranted. The findings of this research can be summarized in the following 
model where we hypothesize that there are two distinct translation systems that 
are coordinated in order to execute the EMT program. 
  
Figure 21. Proposed model of how the proliferative translation program can be 
reduced in order to allow the execution of the pro-mesenchymal/pro-migratory 
translation program. The model incorporates findings from Prakash et al  and Dass 
et al. 
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CHAPTER 3 
CONCLUSION AND FUTURE DIRECTION 
In the course of these studies we have endeavored to understand the 
molecular mechanisms of how tumours develop and subsequently how they are 
disseminated to other organ systems through metastatic spread. What has 
come to light is the importance of translation control and perhaps more 
surprisingly the importance of rDNA transcription. We were able to demonstrate 
that rDNA transcription plays a key role in facilitating how cells go through EMT 
and perhaps more surprisingly that changes in rDNA transcription can directly 
influence gene expression and alter translation programs.  
3.1 rDNA TRANSCRIPTION DRIVES PROLIFERATION AND 
DIFFERENTIATION 
The importance of rDNA transcription was highlighted as a functional way 
Wnt5a exerts its tumour suppressive effect and lead to the observation that 
there are endogenous signals that are responsible for reducing rDNA 
transcription in addition to those previously identified as having increased rDNA 
transcription121–123. Given the importance of rDNA transcription to the creation 
of new ribosomes, the energetic cost of ribosome production and critical role 
ribosome concentration plays in cell cycle it is not surprising that there are 
signaling systems in place that tightly regulate rDNA transcription124–127. 
The role of rDNA transcription has not yet been implicated in the process of 
EMT nor has it directly been linked to the dissemination of cancerous cells. In 
the manuscript Prakash et al. we were able to demonstrate that there is an 
induction of rDNA transcription in the absence of proliferation. The first time, to 
the best of our knowledge, that the uncoupling of rDNA transcription occurs as 
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cells go through EMT in a multitude of systems. There is a strong implication of 
the uncoupling of rDNA transcription and a cellular identity switch being a 
general phenomenon that occurs within multiple contexts including both 
developmental and disease states. 
In order to understand what role, if any, the increased rDNA transcription 
has on the process of EMT we implemented a modified ribosome profiling 
method. In this case we did not biochemically remove rRNA using subtractive 
hybridization methods nor did we remove them bioinformatically, in fact, all RNA 
sequences retrieved were analyzed. Working on the hypothesis that rDNA 
transcription and by extension the making of new ribosomes altered the 
translational landscape of cells that are going through EMT. Ribosome profiling 
would allow for a global snap shot of the translational program, the first such 
overview, as cells transition through EMT. 
3.2 CHANGES TO THE TRANSLATION MACHINERY IN EMT ARE 
PERVASIVE 
Upon implementation and subsequent analysis of the ribosome profiling data 
we observed the first evidence of translation control that is present as cells go 
through EMT. Surprisingly, in the NMuMG system, approximately 40% of all 
genes changes on a translation level were changed only on a translation level 
without the corresponding change in mRNA transcript level. That there was 
such a large degree of global translation control was unexpected and that it 
would be as pervasive was not previously documented. 
The global changes in translation was not only restricted to transcripts that 
changes only on a translation level, upon further investigation we observed 
changes to translation elongation factors, initiation factors, tRNAs, tRNA 
delivery complexes and aminoacyl synthetases. In fact, there was rarely a part 
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of the global translation machinery that was unchanged. Perhaps the most 
surprising observation was the changes in localization of translation related 
proteins, with a small example of such proteins like Eif4a1, P70S6K and Eif3c 
going to the nucleus. Such wide-scale trafficking of translation related proteins 
to the nucleus has not previously been reported in the context of EMT. It is worth 
of further exploration and study in order to understand the signal that instructs 
the proteins to go to the nucleus. 
3.3 mTOR SIGNALING IS REDUCED AS CELLS GO THROUGH EMT 
Perhaps the most striking observation that came from these studies was the 
reduction of mTOR as cells transition from one cell identity to another. The 
observation that mTOR signaling is reduced may be a functional cause of the 
lack of proliferation noted in the Prakash et al manuscript. It also demonstrated 
that global translation as a whole was reduced as cells made the transition. The 
observation strongly argues that there are two distinct and independent 
translation programs in EMT that must be coordinated in order for cells to 
execute the EMT program. 
These observations argue that there is a pro-proliferative mTOR driven 
translation program that consumes the majority of the cells translation capacity 
in addition to that there is a pro-mesenchymal/pro-migratory translation that can 
be executed in the context of a reduced translational background. We were able 
to identify several pro-mesenchymal genes that are regulated only on a 
translational level. These results have been recapitulated in multiple systems, 
particularly in a developmental system like the chick in which there is 
endogenous levels of multiple signaling pathways. 
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3.4 GLOBAL TRANSLATION PROGRAMS IN EMT HINGE ON rDNA 
TRANSCRIPTION 
Current thinking has mTOR signaling as a unidirectional master translation 
regulation pathway. However, in the context of increased rDNA transcription 
and its correspondent uncoupling during EMT we were able to demonstrate that 
you can alter mTOR signaling by reducing rDNA transcription. This is the first 
observation showing that mTOR signaling status could be altered merely by 
restricting rDNA transcription. The alterations were not merely restricted to the 
activity status of mTOR and accompanying kinases (Akt) but to mTOR sensitive 
genes (like ribosomal proteins). 
The implication of this observation is that there must be a direct monitoring 
or feedback loop that allows mTOR to be intimately informed of the status of 
rDNA transcription. This observation itself is somewhat intuitive given that 
mTOR can regulate translation in response to nutrient availability. It would make 
sense that there would be some feedback mechanisms in order to also co-
ordinate ribosome biogenesis with nutrient availability and translational need. 
3.5 FUTURE DIRECTIONS 
In order to truly understand the ramifications of the findings put forth within 
this thesis, further study into how rDNA transcription is organized and what 
actually takes place within the nucleus upon rDNA transcription is needed. At 
this point in time there is a paucity of understanding about the intricacies and 
ramifications of nucleolar biology, particularly how proteins are trafficked into 
and out of the nucleolus or potentially how nucleolar shape alters the function. 
Though there have been some reviews there have yet to be studies linking these 
observation to functional biological consequences or disease states128,129. It is 
my belief that the shape and size of the nucleolus is dependent on the rate of 
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rRNA transcription as the rRNA forms a structural component of the nucleolus. 
This hypothesis can be tested in future work. 
In principle given our demonstrated ability to ribosome profile small amounts 
of material (5 pmols of ribosomes) it may be possible to use cell sorting 
techniques in order to isolate small amounts of biologically relevant cells to 
ribosome profile them in order to determine how their translation landscapes are 
altered. It would also be possible to detect changes in all three RNA 
polymerases in heterogenous populations like those that occur in tumors. 
A stumbling block to determining different rDNA sequences is that the 
genomic sequence of all rDNA genes for the human and the mouse are not 
known. This lack of information makes it difficult to get primers or develop tools 
to explore whether or not there may be different rDNAs (at a sequence level) 
that are expressed in terms of the different translation programs or in another 
context dependent manner. 
A key finding that also emerged from these studies was that translation 
elongation inhibitors can selectively target cells that are going through EMT. 
The translation landscape is sufficiently altered that one can selectively target 
these cells with translation elongation inhibitors. In addition, there has been in 
vivo work in mice demonstrating that reducing rDNA transcription using the Pol 
I inhibitor CX5461 can both reduce tumor volume and metastasis. These 
observations are worthy of follow up studies particularly given the fact that using 
both proliferation inhibitors as well as translation inhibitors in combination may 
be of better therapeutic value to patients in treating both the primary tumour and 
potentially any metastatic spread. 
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APPENDIX 
Reagents needed for NMuMG Growth and Ribosome Profiling 
Media composition for NMuMG cells: 
500 mL DMEM (High Glucose [4.5 g/L] from Gibco/Invitrogen Cat#11965-018 
(12 bottles)) 
10% (50 mL) Fetal Bovine Serum (Atlanta Biologicals Cat# S11150  
Lot# B1040) 
1% (5mL) Penicillin/Streptomycin (Gibco/Invitrogen Cat# 15140) 
Insulin @ final concentration of 10 μg/mL (500μL of a 10mg/mL insulin solution 
from bovine pancreas (Sigma Cat#I0516-5ML)) 
Reagent List 
DMEM (High Glucose [4.5 g/L] from Gibco/Invitrogen Cat#11965-018 
Atlanta Biologicals Cat# S11150 Lot # B1040 
Penicillin/Streptomycin Gibco/Invitrogen Cat# 15140 
10 mg/mL insulin solution from bovine pancreas (Sigma Cat# I0516-5ML) 
Recombinant Human TGF-beta-1, CF (R&D systems 240-B-002/CF) 
10 cm tissue culture plates Corning Cat# 430167 
15 cm tissue culture plates Corning Cat# 430599 
T225 Tissue Culture Flasks BD Cat# 353138  
(Falcon vented cap sterile tissue culture flasks) 
Cycloheximide EMD Millipore 239764-1GM 
TGFβ1 Re-suspension: 
TGFβ1 should be re-suspended using a 0.1% BSA/ 4mM HCl buffer. I have a 
stock solution of the re-suspension buffer in the 4 °C fridge in cell culture. Stock 
solution of TGFβ1 should be 10 ng/μL. 
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PCR Primers for Library Indexing: 
Forward PCR primer: 
5′-AATGATACGGCGACCACCGAGATCTACAC-3′ 
ACGACT 
CAAGCAGAAGACGGCATACGAGATAGTCGTGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
ATCAGT 
CAAGCAGAAGACGGCATACGAGATACTGATGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
CAGCAT 
CAAGCAGAAGACGGCATACGAGATATGCTGGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
CGACGT 
CAAGCAGAAGACGGCATACGAGATACGTCGGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
GCAGCT 
CAAGCAGAAGACGGCATACGAGATAGCTGCGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
TACGAT 
CAAGCAGAAGACGGCATACGAGATATCGTAGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
CTGACG 
CAAGCAGAAGACGGCATACGAGATCGTCAGGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
GCTACG 
CAAGCAGAAGACGGCATACGAGATCGTAGCGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
Size Marker Sequences: 
NI-NI-42 
5'-AUGUACACGGAGUCGAGCUCAACCCGCAACGCGACAACGCGA-(Phos)-3' 
NI-NI-19 
5'-AUGUACACGGAGUCGAGCUCAACCCGCAACGCGA-(Phos)-3'. 
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NI-NI-20 
5'-AUGUACACGGAGUCGACCCAACGCGA-(Phos)-3' 
NI-NI-18 
5'-AUGUACACGGAGUCGACC-(Phos)-3' 
Cloning Linker: 
IDT Cloning Linker 1 
/5rApp/CTGTAGGCACCATCAAT/3ddC 
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